15 October 2019
We've extended funding for the Etanercept (ETN) Cohort Study for a further year up to the end of December 2020.
This support shows our commitment to ongoing research and discovering more about new treatments and their effects on children and young people with Juvenile Idiopathic Arthritis (JIA).
Over the next five years, it's likely that there will be increased use of biosimilars in children and young people. By continuing to collect data from these individuals on the patient register, we'll help to address some of the key research questions in this area as well as contributing and collaborating with ongoing JIA initiatives in Europe and the USA.
In the future, we hope to work with our colleagues at Versus Arthritis to combine with the Biologics for Children with Rheumatic Diseases (BCRD) study, also based at the University of Manchester, in a joint funding venture for the two studies.
For more information about the two studies please click here.